Medline Inc. (MDLN) Stock Competitors & Peer Comparison
See (MDLN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDLN | $37.09 | -0.64% | 31.4B | 32.54 | $1.14 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.58% |
| BDX | $145.16 | -0.25% | 52.6B | 25.35 | $5.73 | +2.58% |
| ALC | $65.84 | -0.68% | 32.1B | 39.43 | $1.67 | +0.55% |
| WST | $329.58 | -0.56% | 23.3B | 44.20 | $7.46 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.58% |
| COO | $67.35 | -0.61% | 13.1B | 57.08 | $1.18 | N/A |
| BAX | $20.46 | -1.68% | 10.6B | -10.73 | -$1.91 | +0.97% |
| ATR | $120.65 | +2.18% | 7.7B | 20.66 | $5.84 | +1.57% |
Stock Comparison
MDLN vs BDXA Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, MDLN is priced at $37.09, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas BDXA's P/E ratio is 21.44. In terms of profitability, MDLN's ROE is +0.07%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, MDLN is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check BDXA's competition here
MDLN vs BDX Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, BDX has a market cap of 52.6B. Regarding current trading prices, MDLN is priced at $37.09, while BDX trades at $145.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas BDX's P/E ratio is 25.35. In terms of profitability, MDLN's ROE is +0.07%, compared to BDX's ROE of +0.05%. Regarding short-term risk, MDLN is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check BDX's competition here
MDLN vs ALC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ALC has a market cap of 32.1B. Regarding current trading prices, MDLN is priced at $37.09, while ALC trades at $65.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ALC's P/E ratio is 39.43. In terms of profitability, MDLN's ROE is +0.07%, compared to ALC's ROE of +0.04%. Regarding short-term risk, MDLN is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ALC's competition here
MDLN vs WST Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, WST has a market cap of 23.3B. Regarding current trading prices, MDLN is priced at $37.09, while WST trades at $329.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas WST's P/E ratio is 44.20. In terms of profitability, MDLN's ROE is +0.07%, compared to WST's ROE of +0.18%. Regarding short-term risk, MDLN is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check WST's competition here
MDLN vs HOLX Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, MDLN is priced at $37.09, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas HOLX's P/E ratio is 31.54. In terms of profitability, MDLN's ROE is +0.07%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, MDLN is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check HOLX's competition here
MDLN vs BDXB Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, MDLN is priced at $37.09, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas BDXB's P/E ratio is 7.60. In terms of profitability, MDLN's ROE is +0.07%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, MDLN is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check BDXB's competition here
MDLN vs COO Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, COO has a market cap of 13.1B. Regarding current trading prices, MDLN is priced at $37.09, while COO trades at $67.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas COO's P/E ratio is 57.08. In terms of profitability, MDLN's ROE is +0.07%, compared to COO's ROE of +0.03%. Regarding short-term risk, MDLN is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check COO's competition here
MDLN vs BAX Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, BAX has a market cap of 10.6B. Regarding current trading prices, MDLN is priced at $37.09, while BAX trades at $20.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas BAX's P/E ratio is -10.73. In terms of profitability, MDLN's ROE is +0.07%, compared to BAX's ROE of -0.16%. Regarding short-term risk, MDLN is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check BAX's competition here
MDLN vs ATR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, MDLN is priced at $37.09, while ATR trades at $120.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ATR's P/E ratio is 20.66. In terms of profitability, MDLN's ROE is +0.07%, compared to ATR's ROE of +0.14%. Regarding short-term risk, MDLN is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check ATR's competition here
MDLN vs RGEN Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, MDLN is priced at $37.09, while RGEN trades at $131.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas RGEN's P/E ratio is 144.71. In terms of profitability, MDLN's ROE is +0.07%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, MDLN is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check RGEN's competition here
MDLN vs AVTR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, AVTR has a market cap of 6.5B. Regarding current trading prices, MDLN is priced at $37.09, while AVTR trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas AVTR's P/E ratio is -11.83. In terms of profitability, MDLN's ROE is +0.07%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, MDLN is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check AVTR's competition here
MDLN vs TFX Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, MDLN is priced at $37.09, while TFX trades at $127.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas TFX's P/E ratio is 1827.06. In terms of profitability, MDLN's ROE is +0.07%, compared to TFX's ROE of -0.28%. Regarding short-term risk, MDLN is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check TFX's competition here
MDLN vs BLCO Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, BLCO has a market cap of 5.4B. Regarding current trading prices, MDLN is priced at $37.09, while BLCO trades at $14.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas BLCO's P/E ratio is -24.24. In terms of profitability, MDLN's ROE is +0.07%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, MDLN is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check BLCO's competition here
MDLN vs STVN Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, STVN has a market cap of 4.5B. Regarding current trading prices, MDLN is priced at $37.09, while STVN trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas STVN's P/E ratio is 28.06. In terms of profitability, MDLN's ROE is +0.07%, compared to STVN's ROE of +0.10%. Regarding short-term risk, MDLN is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check STVN's competition here
MDLN vs MMSI Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, MMSI has a market cap of 4B. Regarding current trading prices, MDLN is priced at $37.09, while MMSI trades at $67.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas MMSI's P/E ratio is 29.17. In terms of profitability, MDLN's ROE is +0.07%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, MDLN is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check MMSI's competition here
MDLN vs ICUI Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ICUI has a market cap of 3.6B. Regarding current trading prices, MDLN is priced at $37.09, while ICUI trades at $142.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ICUI's P/E ratio is 76.56. In terms of profitability, MDLN's ROE is +0.07%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, MDLN is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ICUI's competition here
MDLN vs HAE Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, MDLN is priced at $37.09, while HAE trades at $74.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas HAE's P/E ratio is 36.32. In terms of profitability, MDLN's ROE is +0.07%, compared to HAE's ROE of +0.11%. Regarding short-term risk, MDLN is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check HAE's competition here
MDLN vs WRBY Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, WRBY has a market cap of 3.1B. Regarding current trading prices, MDLN is priced at $37.09, while WRBY trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas WRBY's P/E ratio is 2517.00. In terms of profitability, MDLN's ROE is +0.07%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, MDLN is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check WRBY's competition here
MDLN vs LMAT Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, MDLN is priced at $37.09, while LMAT trades at $93.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas LMAT's P/E ratio is 34.33. In terms of profitability, MDLN's ROE is +0.07%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, MDLN is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check LMAT's competition here
MDLN vs XRAY Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, MDLN is priced at $37.09, while XRAY trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas XRAY's P/E ratio is -3.32. In terms of profitability, MDLN's ROE is +0.07%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, MDLN is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check XRAY's competition here
MDLN vs NVCR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, MDLN is priced at $37.09, while NVCR trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NVCR's P/E ratio is -11.43. In terms of profitability, MDLN's ROE is +0.07%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, MDLN is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check NVCR's competition here
MDLN vs PLSE Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, PLSE has a market cap of 1.7B. Regarding current trading prices, MDLN is priced at $37.09, while PLSE trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas PLSE's P/E ratio is -22.83. In terms of profitability, MDLN's ROE is +0.07%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, MDLN is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check PLSE's competition here
MDLN vs STAA Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, MDLN is priced at $37.09, while STAA trades at $28.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas STAA's P/E ratio is -68.86. In terms of profitability, MDLN's ROE is +0.07%, compared to STAA's ROE of -0.06%. Regarding short-term risk, MDLN is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check STAA's competition here
MDLN vs ATRC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, MDLN is priced at $37.09, while ATRC trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ATRC's P/E ratio is -279.80. In terms of profitability, MDLN's ROE is +0.07%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, MDLN is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check ATRC's competition here
MDLN vs BLFS Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, MDLN is priced at $37.09, while BLFS trades at $26.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas BLFS's P/E ratio is -109.83. In terms of profitability, MDLN's ROE is +0.07%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, MDLN is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check BLFS's competition here
MDLN vs KMTS Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, MDLN is priced at $37.09, while KMTS trades at $19.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas KMTS's P/E ratio is -3.52. In terms of profitability, MDLN's ROE is +0.07%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, MDLN is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check KMTS's competition here
MDLN vs AZTA Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, AZTA has a market cap of 1.1B. Regarding current trading prices, MDLN is priced at $37.09, while AZTA trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas AZTA's P/E ratio is -9.60. In terms of profitability, MDLN's ROE is +0.07%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, MDLN is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check AZTA's competition here
MDLN vs QDEL Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, QDEL has a market cap of 962.9M. Regarding current trading prices, MDLN is priced at $37.09, while QDEL trades at $14.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas QDEL's P/E ratio is -0.79. In terms of profitability, MDLN's ROE is +0.07%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, MDLN is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check QDEL's competition here
MDLN vs ATRI Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, MDLN is priced at $37.09, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ATRI's P/E ratio is 64.50. In terms of profitability, MDLN's ROE is +0.07%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, MDLN is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ATRI's competition here
MDLN vs NNNN Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NNNN has a market cap of 724.2M. Regarding current trading prices, MDLN is priced at $37.09, while NNNN trades at $16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NNNN's P/E ratio is 110.00. In terms of profitability, MDLN's ROE is +0.07%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, MDLN is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check NNNN's competition here
MDLN vs ANGO Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ANGO has a market cap of 502M. Regarding current trading prices, MDLN is priced at $37.09, while ANGO trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ANGO's P/E ratio is -15.99. In terms of profitability, MDLN's ROE is +0.07%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, MDLN is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ANGO's competition here
MDLN vs OSUR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, OSUR has a market cap of 297.4M. Regarding current trading prices, MDLN is priced at $37.09, while OSUR trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas OSUR's P/E ratio is -4.11. In terms of profitability, MDLN's ROE is +0.07%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, MDLN is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check OSUR's competition here
MDLN vs UTMD Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, UTMD has a market cap of 214.8M. Regarding current trading prices, MDLN is priced at $37.09, while UTMD trades at $67.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas UTMD's P/E ratio is 19.96. In terms of profitability, MDLN's ROE is +0.07%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, MDLN is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check UTMD's competition here
MDLN vs SMTI Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, SMTI has a market cap of 207.9M. Regarding current trading prices, MDLN is priced at $37.09, while SMTI trades at $22.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas SMTI's P/E ratio is 378.17. In terms of profitability, MDLN's ROE is +0.07%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, MDLN is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check SMTI's competition here
MDLN vs PDEX Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, PDEX has a market cap of 199M. Regarding current trading prices, MDLN is priced at $37.09, while PDEX trades at $62.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas PDEX's P/E ratio is 17.17. In terms of profitability, MDLN's ROE is +0.07%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, MDLN is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check PDEX's competition here
MDLN vs KRMD Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, KRMD has a market cap of 181M. Regarding current trading prices, MDLN is priced at $37.09, while KRMD trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas KRMD's P/E ratio is -78.80. In terms of profitability, MDLN's ROE is +0.07%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, MDLN is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check KRMD's competition here
MDLN vs INFU Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, INFU has a market cap of 178.9M. Regarding current trading prices, MDLN is priced at $37.09, while INFU trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas INFU's P/E ratio is 23.96. In terms of profitability, MDLN's ROE is +0.07%, compared to INFU's ROE of +0.14%. Regarding short-term risk, MDLN is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check INFU's competition here
MDLN vs STXS Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, STXS has a market cap of 177.9M. Regarding current trading prices, MDLN is priced at $37.09, while STXS trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas STXS's P/E ratio is -7.58. In terms of profitability, MDLN's ROE is +0.07%, compared to STXS's ROE of -1.53%. Regarding short-term risk, MDLN is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check STXS's competition here
MDLN vs MBOT Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, MBOT has a market cap of 82.9M. Regarding current trading prices, MDLN is priced at $37.09, while MBOT trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas MBOT's P/E ratio is -7.00. In terms of profitability, MDLN's ROE is +0.07%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, MDLN is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check MBOT's competition here
MDLN vs AKYA Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, MDLN is priced at $37.09, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas AKYA's P/E ratio is -1.34. In terms of profitability, MDLN's ROE is +0.07%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, MDLN is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check AKYA's competition here
MDLN vs NYXH Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NYXH has a market cap of 62.6M. Regarding current trading prices, MDLN is priced at $37.09, while NYXH trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NYXH's P/E ratio is -0.64. In terms of profitability, MDLN's ROE is +0.07%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, MDLN is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check NYXH's competition here
MDLN vs STSS Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, STSS has a market cap of 55M. Regarding current trading prices, MDLN is priced at $37.09, while STSS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas STSS's P/E ratio is -0.02. In terms of profitability, MDLN's ROE is +0.07%, compared to STSS's ROE of -1.66%. Regarding short-term risk, MDLN is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check STSS's competition here
MDLN vs DXR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, DXR has a market cap of 51M. Regarding current trading prices, MDLN is priced at $37.09, while DXR trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas DXR's P/E ratio is 6.17. In terms of profitability, MDLN's ROE is +0.07%, compared to DXR's ROE of +0.22%. Regarding short-term risk, MDLN is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check DXR's competition here
MDLN vs OMIC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, MDLN is priced at $37.09, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas OMIC's P/E ratio is -0.58. In terms of profitability, MDLN's ROE is +0.07%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, MDLN is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check OMIC's competition here
MDLN vs IGAP Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, MDLN is priced at $37.09, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas IGAP's P/E ratio is -10.52. In terms of profitability, MDLN's ROE is +0.07%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, MDLN is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check IGAP's competition here
MDLN vs ZTEK Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ZTEK has a market cap of 48.9M. Regarding current trading prices, MDLN is priced at $37.09, while ZTEK trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ZTEK's P/E ratio is -7.57. In terms of profitability, MDLN's ROE is +0.07%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, MDLN is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check ZTEK's competition here
MDLN vs EKSO Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, EKSO has a market cap of 46.1M. Regarding current trading prices, MDLN is priced at $37.09, while EKSO trades at $19.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas EKSO's P/E ratio is -3.72. In terms of profitability, MDLN's ROE is +0.07%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, MDLN is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check EKSO's competition here
MDLN vs POCI Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, POCI has a market cap of 45.6M. Regarding current trading prices, MDLN is priced at $37.09, while POCI trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas POCI's P/E ratio is -9.22. In terms of profitability, MDLN's ROE is +0.07%, compared to POCI's ROE of -0.37%. Regarding short-term risk, MDLN is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check POCI's competition here
MDLN vs NEPH Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NEPH has a market cap of 36.6M. Regarding current trading prices, MDLN is priced at $37.09, while NEPH trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NEPH's P/E ratio is 48.14. In terms of profitability, MDLN's ROE is +0.07%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, MDLN is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check NEPH's competition here
MDLN vs MLSS Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, MLSS has a market cap of 30M. Regarding current trading prices, MDLN is priced at $37.09, while MLSS trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas MLSS's P/E ratio is -5.68. In terms of profitability, MDLN's ROE is +0.07%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, MDLN is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check MLSS's competition here
MDLN vs SDC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, MDLN is priced at $37.09, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas SDC's P/E ratio is -0.03. In terms of profitability, MDLN's ROE is +0.07%, compared to SDC's ROE of -1.96%. Regarding short-term risk, MDLN is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check SDC's competition here
MDLN vs HBIO Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, HBIO has a market cap of 26.8M. Regarding current trading prices, MDLN is priced at $37.09, while HBIO trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas HBIO's P/E ratio is -2.77. In terms of profitability, MDLN's ROE is +0.07%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, MDLN is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check HBIO's competition here
MDLN vs IVC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, MDLN is priced at $37.09, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas IVC's P/E ratio is -0.79. In terms of profitability, MDLN's ROE is +0.07%, compared to IVC's ROE of -0.46%. Regarding short-term risk, MDLN is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check IVC's competition here
MDLN vs RGNT Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, RGNT has a market cap of 24.8M. Regarding current trading prices, MDLN is priced at $37.09, while RGNT trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas RGNT's P/E ratio is -0.26. In terms of profitability, MDLN's ROE is +0.07%, compared to RGNT's ROE of N/A. Regarding short-term risk, MDLN is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check RGNT's competition here
MDLN vs RVP Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, MDLN is priced at $37.09, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas RVP's P/E ratio is -3.00. In terms of profitability, MDLN's ROE is +0.07%, compared to RVP's ROE of -0.08%. Regarding short-term risk, MDLN is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check RVP's competition here
MDLN vs ZJYL Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ZJYL has a market cap of 18.7M. Regarding current trading prices, MDLN is priced at $37.09, while ZJYL trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ZJYL's P/E ratio is 11.95. In terms of profitability, MDLN's ROE is +0.07%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, MDLN is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check ZJYL's competition here
MDLN vs ARTC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ARTC has a market cap of 16.1M. Regarding current trading prices, MDLN is priced at $37.09, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ARTC's P/E ratio is N/A. In terms of profitability, MDLN's ROE is +0.07%, compared to ARTC's ROE of N/A. Regarding short-term risk, MDLN is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ARTC's competition here
MDLN vs FEMY Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, FEMY has a market cap of 11.6M. Regarding current trading prices, MDLN is priced at $37.09, while FEMY trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas FEMY's P/E ratio is -0.80. In terms of profitability, MDLN's ROE is +0.07%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, MDLN is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check FEMY's competition here
MDLN vs NSTG Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, MDLN is priced at $37.09, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NSTG's P/E ratio is -0.03. In terms of profitability, MDLN's ROE is +0.07%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, MDLN is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check NSTG's competition here
MDLN vs NXGL Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NXGL has a market cap of 4.9M. Regarding current trading prices, MDLN is priced at $37.09, while NXGL trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NXGL's P/E ratio is -1.33. In terms of profitability, MDLN's ROE is +0.07%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, MDLN is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check NXGL's competition here
MDLN vs POAI Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, MDLN is priced at $37.09, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas POAI's P/E ratio is -0.03. In terms of profitability, MDLN's ROE is +0.07%, compared to POAI's ROE of -107.05%. Regarding short-term risk, MDLN is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check POAI's competition here
MDLN vs LUCY Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, LUCY has a market cap of 3.4M. Regarding current trading prices, MDLN is priced at $37.09, while LUCY trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas LUCY's P/E ratio is -0.56. In terms of profitability, MDLN's ROE is +0.07%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, MDLN is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check LUCY's competition here
MDLN vs NXGLW Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, NXGLW has a market cap of 3M. Regarding current trading prices, MDLN is priced at $37.09, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, MDLN's ROE is +0.07%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, MDLN is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check NXGLW's competition here
MDLN vs MHUA Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, MDLN is priced at $37.09, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas MHUA's P/E ratio is 0.25. In terms of profitability, MDLN's ROE is +0.07%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, MDLN is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check MHUA's competition here
MDLN vs GMVD Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, MDLN is priced at $37.09, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas GMVD's P/E ratio is -0.01. In terms of profitability, MDLN's ROE is +0.07%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, MDLN is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check GMVD's competition here
MDLN vs GMVDW Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, MDLN is priced at $37.09, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas GMVDW's P/E ratio is N/A. In terms of profitability, MDLN's ROE is +0.07%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, MDLN is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check GMVDW's competition here
MDLN vs AVGR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, MDLN is priced at $37.09, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas AVGR's P/E ratio is -0.05. In terms of profitability, MDLN's ROE is +0.07%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, MDLN is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check AVGR's competition here
MDLN vs STSSW Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, STSSW has a market cap of 887.9K. Regarding current trading prices, MDLN is priced at $37.09, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas STSSW's P/E ratio is -0.04. In terms of profitability, MDLN's ROE is +0.07%, compared to STSSW's ROE of N/A. Regarding short-term risk, MDLN is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check STSSW's competition here
MDLN vs LUCYW Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, MDLN is priced at $37.09, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas LUCYW's P/E ratio is N/A. In terms of profitability, MDLN's ROE is +0.07%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, MDLN is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check LUCYW's competition here
MDLN vs GCTK Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, GCTK has a market cap of 225.3K. Regarding current trading prices, MDLN is priced at $37.09, while GCTK trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas GCTK's P/E ratio is 0.06. In terms of profitability, MDLN's ROE is +0.07%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, MDLN is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check GCTK's competition here
MDLN vs WOK Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, WOK has a market cap of 289. Regarding current trading prices, MDLN is priced at $37.09, while WOK trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas WOK's P/E ratio is N/A. In terms of profitability, MDLN's ROE is +0.07%, compared to WOK's ROE of -0.07%. Regarding short-term risk, MDLN is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for MDLN.Check WOK's competition here
MDLN vs APR Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, APR has a market cap of 0. Regarding current trading prices, MDLN is priced at $37.09, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas APR's P/E ratio is 22.59. In terms of profitability, MDLN's ROE is +0.07%, compared to APR's ROE of +9.81%. Regarding short-term risk, MDLN is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check APR's competition here
MDLN vs HRC Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, HRC has a market cap of 0. Regarding current trading prices, MDLN is priced at $37.09, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas HRC's P/E ratio is 41.92. In terms of profitability, MDLN's ROE is +0.07%, compared to HRC's ROE of +0.14%. Regarding short-term risk, MDLN is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check HRC's competition here
MDLN vs ALOG Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, MDLN is priced at $37.09, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ALOG's P/E ratio is N/A. In terms of profitability, MDLN's ROE is +0.07%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, MDLN is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ALOG's competition here
MDLN vs IVTY Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, MDLN is priced at $37.09, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas IVTY's P/E ratio is N/A. In terms of profitability, MDLN's ROE is +0.07%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, MDLN is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check IVTY's competition here
MDLN vs IIN Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, IIN has a market cap of 0. Regarding current trading prices, MDLN is priced at $37.09, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas IIN's P/E ratio is 226.45. In terms of profitability, MDLN's ROE is +0.07%, compared to IIN's ROE of -0.00%. Regarding short-term risk, MDLN is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check IIN's competition here
MDLN vs ATRS Comparison June 2026
MDLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDLN stands at 31.4B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, MDLN is priced at $37.09, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDLN currently has a P/E ratio of 32.54, whereas ATRS's P/E ratio is 14.95. In terms of profitability, MDLN's ROE is +0.07%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, MDLN is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for MDLN.Check ATRS's competition here